Floatz logo

Glatiramer

Rectal Neoplasms

Institut du Cancer de Montpellier - Val d'Aurelleprotein_peptideN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

20 Active assets in the Rectal Neoplasms cohort.

Asset / SponsorPhaseRating
Eloxatin
Chongqing University Cancer Hospital
Phase 3BB
FLUOROURACILUM
Pei-Rong Ding
Phase 3BB
Ertapenem
University of Ulm
Phase 4BB
PROPOFOL
Uppsala University
Phase 4BB
Sevoflurane
Uppsala University
Phase 4BB

View all 44 →

Same molecule, other indications

Glatiramer is also rated in:

relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
79 / 100
View asset →
multiple sclerosisDormant
BB
Indicative ·
67 / 100
View asset →
secondary progressive multiple sclerosisDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →